论文部分内容阅读
作者报告了联合应用大剂量的白细胞介素-2(IL-2)与α_(2b)-干扰素,治疗恶性肿瘤患者的Ⅰ期研究效果。
The authors report the results of a Phase I study of the combination of large doses of interleukin-2 (IL-2) and α_(2b)-interferon in patients with malignant tumors.